oral+semaglutide+approval Novo Nordisk's Wegovy® pill (oral semaglutide 25 mg, once daily) has just been approved by the US FDA as the first oral GLP‑1 receptor agonist for long‑term weight management and CV risk Early uptake of Wegovy pill

But, they tend to be more severe and need treatment with antibiotics

On the September 2025 episode of her Self-Conscious podcast, she revealed she tried GLP-1 after finding it difficult to lose weight post-miscarriage, describing how her body felt completely stuck during that time

What the Evidence Says About GLP-1 Medications: An Honest Summary GLP-1 receptor agonists work through a mechanism that's been well-characterized in peer-reviewed medical literature and forms the basis for the clinical evidence that's made this drug class one of the most discussed pharmacological developments in obesity medicine in a generation

Generally this occurs after month 5 or 6 after continuous increases to dosaging

The patient reported dysphagia and belching, which were also present even before the initiation of semaglutide treatment, and these symptoms resolved spontaneously in the following months

Its no surprise that this medication has been embraced by many seeking a safe and effective method for long-term weight loss